Coherus Biosciences | CHRS - Zinsaufwendungen Für Schuld

Aktienkurs
1.52
Täglich Wechseln
-0.09 -5.59%
Monatlich
-6.17%
Jährlich
47.57%
Q1 Prognose
1.47




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 4.83M 359.32M 2025-12
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amarin USD 3K 5K 2024-12
Amgen USD 653M 32M 2025-12
Baxter International USD 58M 14M 2025-09
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Fujifilm JPY 1.29B 907M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Merck USD 412M 85M 2025-12
Myriad Genetics USD 4.4M 600K 2025-12
Pacira USD 3.89M 387K 2025-12
Perrigo USD 10.08B 10.04B 2025-09
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 311K 2025-12
Zoetis USD 57M 1000K 2025-12